Research Report University Hospital for clinical assessment BRF 115532

Abstract

A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection

Keywords

• melanoma after surgical resection
• dabrafenib (GSK2118436)
• trametinib (GSK1120212)